BR
Brooks Laboratories Ltd (BROOKS)
₹56.51
Mkt cap
₹181 Cr
P/E ratio
13.70
P/B
1.36
Div yield
0.00%
ROE
22.00%
ROCE
21.20%
EPS (TTM)
₹4.12
Book value
₹42
52W range
36–152
Sector
Healthcare
Price history
Previous close
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment [1]
NSE BROOKSBSE 533543
Health check
Mixed
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBearish
52-week range
−62.92% from high₹57
₹36+55.67% from low₹152
Current
₹56.51
Prev close
₹56.55
Day
−0.07%
Price performance
1D
−0.09%
1W
−4.38%
1M
−18.45%
3M
−21.85%
6M
+20.78%
1Y
−61.59%
YTD
−26.86%
Financials
Revenue, profit & margin
P/E ratio
13.7×
BROOKS is 60% below the sector median of 34.6×
BROOKS13.7×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.70 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 | |
| Expenses | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 | 19.53 | 24.30 | |
| Operating Profit | -3.91 | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -1.50 | -1.26 | 3.13 | 2.52 | 0.73 | 0.68 | -1.34 | |
| OPM % | -24.90% | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -7.31% | -5.40% | 12.27% | 10.75% | 4.41% | 3.36% | -5.84% | |
| Other Income | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 | 1.35 | 0.18 | |
| Interest | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.30 | 0.28 | 0.16 | 0.09 | 0.21 | |
| Depreciation | 0.44 | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 | |
| Profit before tax | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 | 5.50 | 1.53 | -1.79 | |
| Tax % | 0.00% | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.00% | 13.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 | 5.50 | 1.52 | -1.79 | |
| EPS in Rs | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.50 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −4.86% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26◦ |
| Earnings day | −4.86% |
| +1 day | −7.53% |
| +5 days | −8.54% |
| +15 days | +0.72% |
| +30 days | −13.80% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202652.62%Promoter
Promoters52.62%
FIIs0.00%0.17
DIIs10.38%
Public37.00%0.16
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Brooks Lab. | ₹61.53 | 13.72 | 181 | 0.00% | −2 | −118.68% | 23 | −10.00% | 21.22% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Credit ratings5
Announcements5
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 16 Sep - Company Secretary and Compliance Officer Krutika Rane resigns, effective October 9, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Sep - Newspaper Publication regarding re-lodgement of transfer deed.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 4 SepShareholder Meeting / Postal Ballot-Outcome of AGM 3 SepAnnouncement under Regulation 30 (LODR)-Newspaper Publication 22 Aug - Addendum to the Notice of 24th Annual General Meeting.